首页> 美国卫生研究院文献>Nutrients >Beneficial Effects of Non-Encapsulated or Encapsulated Probiotic Supplementation on Microbiota Composition Intestinal Barrier Functions Inflammatory Profiles and Glucose Tolerance in High Fat Fed Rats
【2h】

Beneficial Effects of Non-Encapsulated or Encapsulated Probiotic Supplementation on Microbiota Composition Intestinal Barrier Functions Inflammatory Profiles and Glucose Tolerance in High Fat Fed Rats

机译:非封装或封装的益生菌补充剂对高脂喂养大鼠的微生物群组成肠道屏障功能炎性分布和葡萄糖耐量的有益影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Development of obesity-associated comorbidities is related to chronic inflammation, which has been linked to gut microbiota dysbiosis. Thus, modulating gut microbiota composition could have positive effects for metabolic disorders, supporting the use of probiotics as potential therapeutics in vivo, which may be enhanced by a microencapsulation technique. Here we investigated the effects of non-encapsulated or pectin-encapsulated probiotic supplementation (Lactobacillus paracasei subsp. paracasei L. casei W8®; L. casei W8) on gut microbiota composition and metabolic profile in high-fat (HF) diet-fed rats. Four male Wistar rat groups (n = 8/group) were fed 10% low-fat, 45% HF, or HF with non-encapsulated or encapsulated L. casei W8 (4 × 107 CFU/g diet) diet for seven weeks. Microbiota composition, intestinal integrity, inflammatory profiles, and glucose tolerance were assessed. Non-encapsulated and pectin-encapsulated probiotic supplementation positively modulated gut microbiota composition in HF-fed male rats. These changes were associated with improvements in gut barrier functions and local and systemic inflammation by non-encapsulated probiotics and improvement in glucose tolerance by encapsulated probiotic treatment. Thus, these findings suggest the potential of using oral non-encapsulated or encapsulated probiotic supplementation to ameliorate obesity-associated metabolic abnormalities.
机译:肥胖相关合并症的发展与慢性炎症有关,慢性炎症与肠道菌群失调有关。因此,调节肠道菌群组成可能对代谢紊乱具有积极作用,从而支持将益生菌用作体内潜在的治疗方法,这可以通过微囊化技术得到增强。在这里,我们研究了非封装或果胶封装的益生菌补充剂(副干酪乳杆菌副干酪亚种干酪乳杆菌W8 ®®®干酪乳杆菌W8)对高脂肠道菌群组成和代谢特征的影响(HF)饮食喂养的大鼠。向四个雄性Wistar大鼠组(n = 8 /组)喂10%低脂,45%HF或HF与未包囊或包囊的干酪乳杆菌W8(4×10 7 CFU / g饮食)饮食七个星期。评估了微生物群组成,肠道完整性,炎症和葡萄糖耐量。未包封和果胶包埋的益生菌补充剂可在HF喂养的雄性大鼠中积极调节肠道菌群组成。这些变化与通过非胶囊化的益生菌改善肠屏障功能以及局部和全身炎症以及通过胶囊化的益生菌治疗改善葡萄糖耐量有关。因此,这些发现表明使用口服非胶囊化或胶囊化益生菌补充剂可改善肥胖相关的代谢异常。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号